Institution
New York University
Education•New York, New York, United States•
About: New York University is a education organization based out in New York, New York, United States. It is known for research contribution in the topics: Population & Poison control. The organization has 72380 authors who have published 165545 publications receiving 8334030 citations. The organization is also known as: NYU & University of the City of New York.
Topics: Population, Poison control, Health care, Cancer, Mental health
Papers published on a yearly basis
Papers
More filters
••
TL;DR: The distinct physiological contexts of EMT and the underlying molecular signaling networks controlled by TGF-β are reviewed.
Abstract: Remarkable phenotype plasticity of epithelial cells underlies morphogenesis, epithelial repair and tumor invasiveness. Detailed understanding of the contextual cues and molecular mediators that control epithelial plasticity will be required in order to develop viable therapeutic approaches targeting epithelial-to-mesenchymal transition (EMT), an advanced manifestation of epithelial plasticity. Members of the transforming growth factor (TGF-β) family of growth factors can initiate and maintain EMT in a variety of biological systems and pathophysiological context by activating major signaling pathways and transcriptional regulators integrated in extensive signaling networks. Here we will review the distinct physiological contexts of EMT and the underlying molecular signaling networks controlled by TGF-β.
1,451 citations
•
TL;DR: In this paper, the authors examine leverage levels and year-to-year changes for several hundred firms between 1984 and 1991 and find that leverage levels are positively related to CEO stock ownership and CEO stock option holdings, and negatively related toCEO tenure and board of directors size.
Abstract: We test the prediction that leverage is inversely associated with managerial entrenchment. We examine leverage levels and year-to-year changes for several hundred firms between 1984 and 1991. We find that leverage levels are positively related to CEO stock ownership and CEO stock option holdings, and negatively related to CEO tenure and board of directors size. While generally consistent with less entrenched CEOs pursuing more leverage, these results are subject to alternative interpretations. We therefore analyze year-to-year changes in leverage around exogenous shocks to corporate governance variables. We find that leverage increases after unsuccessful tender offers and â¬Sforcedâ¬? CEO replacements, and under certain conditions after the arrival of major stockholders. These relations have greater magnitude when the sample is restricted to low-leverage firms, even when 80% of firms are defined as low-leverage. The results are consistent with decreases in entrenchment leading to increases in leverage, and with the majority of firms having less debt than optimal.
1,451 citations
••
TL;DR: Detailed information about the MNE package is given and typical use cases are described while also warning about potential caveats in analysis.
1,447 citations
••
Copenhagen University Hospital1, French Institute of Health and Medical Research2, St George's, University of London3, University of Gothenburg4, The Catholic University of America5, University of Western Australia6, Columbia University7, University of Milan8, New York University9, Forest Research Institute10, University of Amsterdam11, Hacettepe University12, University of Copenhagen13
TL;DR: The robust and specific association between elevated Lp(a) levels and increased cardiovascular disease (CVD)/coronary heart disease (CHD) risk, together with recent genetic findings, indicates that elevated LP(a), like elevated LDL-cholesterol, is causally related to premature CVD/CHD.
Abstract: AIMS: The aims of the study were, first, to critically evaluate lipoprotein(a) [Lp(a)] as a cardiovascular risk factor and, second, to advise on screening for elevated plasma Lp(a), on desirable levels, and on therapeutic strategies. METHODS AND RESULTS: The robust and specific association between elevated Lp(a) levels and increased cardiovascular disease (CVD)/coronary heart disease (CHD) risk, together with recent genetic findings, indicates that elevated Lp(a), like elevated LDL-cholesterol, is causally related to premature CVD/CHD. The association is continuous without a threshold or dependence on LDL- or non-HDL-cholesterol levels. Mechanistically, elevated Lp(a) levels may either induce a prothrombotic/anti-fibrinolytic effect as apolipoprotein(a) resembles both plasminogen and plasmin but has no fibrinolytic activity, or may accelerate atherosclerosis because, like LDL, the Lp(a) particle is cholesterol-rich, or both. We advise that Lp(a) be measured once, using an isoform-insensitive assay, in subjects at intermediate or high CVD/CHD risk with premature CVD, familial hypercholesterolaemia, a family history of premature CVD and/or elevated Lp(a), recurrent CVD despite statin treatment, ≥3% 10-year risk of fatal CVD according to European guidelines, and/or ≥10% 10-year risk of fatal + non-fatal CHD according to US guidelines. As a secondary priority after LDL-cholesterol reduction, we recommend a desirable level for Lp(a) <80th percentile (less than ∼50 mg/dL). Treatment should primarily be niacin 1-3 g/day, as a meta-analysis of randomized, controlled intervention trials demonstrates reduced CVD by niacin treatment. In extreme cases, LDL-apheresis is efficacious in removing Lp(a). CONCLUSION: We recommend screening for elevated Lp(a) in those at intermediate or high CVD/CHD risk, a desirable level <50 mg/dL as a function of global cardiovascular risk, and use of niacin for Lp(a) and CVD/CHD risk reduction.
1,446 citations
••
TL;DR: It is shown that low-dose penicillin (LDP), delivered from birth, induces metabolic alterations and affects ileal expression of genes involved in immunity, indicating that microbiota interactions in infancy may be critical determinants of long-term host metabolic effects.
1,445 citations
Authors
Showing all 73237 results
Name | H-index | Papers | Citations |
---|---|---|---|
Rob Knight | 201 | 1061 | 253207 |
Virginia M.-Y. Lee | 194 | 993 | 148820 |
Frank E. Speizer | 193 | 636 | 135891 |
Stephen V. Faraone | 188 | 1427 | 140298 |
Eric R. Kandel | 184 | 603 | 113560 |
Andrei Shleifer | 171 | 514 | 271880 |
Eliezer Masliah | 170 | 982 | 127818 |
Roderick T. Bronson | 169 | 679 | 107702 |
Timothy A. Springer | 167 | 669 | 122421 |
Alvaro Pascual-Leone | 165 | 969 | 98251 |
Nora D. Volkow | 165 | 958 | 107463 |
Dennis R. Burton | 164 | 683 | 90959 |
Charles N. Serhan | 158 | 728 | 84810 |
Giacomo Bruno | 158 | 1687 | 124368 |
Tomas Hökfelt | 158 | 1033 | 95979 |